Pfizer management check
PFE · Health Care · Pharmaceuticals · CEO Bourla
Filings as of
Closest peers in Pharmaceuticals
- 35LLYLilly (Eli)84
- 181JNJJohnson & Johnson70
- 195ZTSZoetis68
- 261MRKMerck & Co.64
- 277PFEPfizer63
- 335BMYBristol Myers Squibb59
- 369VTRSViatris57
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
016thDetail
$100 invested at the start of fiscal 2021 grew to $86, against $187 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
7842ndDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.57 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.4% of net income
What does the CEO cost owners?
$27.6m pay · $7.8bn net income, FY2025
8785thDetail
$27.6m of reported pay in fiscal 2025, against $7.8bn of net income.
- GoodInsiders are buying
Do they own the stock?
429,173 shares ≈ $11.3m
6 mo: ▲ $3.0m bought · ▼ $135k sold
3637thDetail
The CEO holds 429,173 shares, directly or through trusts (unvested awards not counted): about 0.4 years of pay. 3 insiders bought $3.0m on the open market in the last six months, with their own money, near the lows. Sales: $135k.
- WatchShare count growing
Are owners being diluted?
Diluted shares +0.0% a year; flagged above +2%
Stock pay 1.3% of revenue
5034thDetail
Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.
- Good7 leadership filings in 3 years
Is leadership stable?
7 filings under 8-K 5.02 in 3 years
CEO: Bourla
9069thDetail
CEO in the pay table: Bourla. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 12, 2026.
Pay tied most to Adjusted Net Income
Other key measuresTotal RevenueAdjusted Diluted EPSCash Flow from Operations
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Bourla | $27.6m | $33.7m | $9.6m | $86 | $187 | $7.8bn |
| 2024 | Bourla | $24.6m | $38.5m | $8.5m | $86 | $151 | $8.0bn |
| 2023 | Bourla | $21.6m | −$62.1m | $6.3m | $88 | $143 | $2.1bn |
| 2022 | Bourla | $33.0m | $5.7m | $14.8m | $149 | $133 | $31.4bn |
| 2021 | Bourla | $24.4m | $115.2m | $9.3m | $167 | $123 | $22.0bn |
Insiders and the CEO's stake
- Chairman & CEO
- Albert Bourla
- Shares held
- 429,173
- At that filing's price
- ≈ $11.3m
- Latest Form 4
- Aug 12, 2026
3 insiders bought $3.0m on the open market in the last six months, with their own money, near the lows. Sales: $135k.
Open-market trades by officers and directors since May 21, 2026.
- BoughtAlbert BourlaChairman & CEO$1.0mAug 12, 2026
- BoughtRonald E BlaylockDirector$999kAug 5, 2026
- BoughtMortimer J BuckleyDirector$960kAug 5, 2026
- SoldJennifer B. DamicoSVP & Controller$135kAug 5, 2026
Leadership and governance on file
All 11 filings
- Nov 3, 2026Leadership change8-K 5.02
- Jun 18, 2026Leadership change8-K 5.02
- Oct 15, 2024Leadership change8-K 5.02
- Jul 26, 2024Leadership change8-K 5.02
- Jul 10, 2024Leadership change8-K 5.02
- Jul 1, 2024Leadership change8-K 5.02
- Dec 12, 2023Leadership change8-K 5.02
- Jul 27, 2023Leadership change8-K 5.02
- Apr 12, 2022Leadership change8-K 5.02
- Dec 15, 2021Leadership change8-K 5.02
- Nov 19, 2021Leadership change8-K 5.02
Latest shareholder vote results: Apr 27, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $2.0bn returned to owners in buybacks and dividends, 3% of net income, and $4.3bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $73.6bn | $91.8bn | $50.9bn | $63.6bn | $62.6bn |
| Net income | $22.0bn | $31.4bn | $2.1bn | $8.0bn | $7.8bn |
| Stock-based pay | $1.2bn | $872.0m | $525.0m | $877.0m | $799.0m |
| Buybacks | $0 | $2.0bn | $0 | $0 | — |
| Dividends | — | — | — | — | — |
| Diluted shares | 5708m | 5733m | 5709m | 5700m | 5713m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.